Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Regulus Therapeutics Inc (RGLS) NPV

Sell:$0.70 Buy:$0.71 Change: $0.0107 (1.54%)
NASDAQ:0.40%
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$0.70
Buy:$0.71
Change: $0.0107 (1.54%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
Sell:$0.70
Buy:$0.71
Change: $0.0107 (1.54%)
Market closed |  Prices as at close on 17 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company's Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.

Contact details

Address:
10628 Science Center Dr Ste 225
SAN DIEGO
92121-1124
United States
Telephone:
+1 (858) 2026300
Website:
www.regulusrx.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
RGLS
ISIN:
US75915K2006
Market cap:
$13.79 million
Shares in issue:
20.82 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Stelios Papadopoulos
    Chairman of the Board
  • Joseph Hagan
    President, Chief Executive Officer, Director
  • Crispina Calsada
    Chief Financial Officer
  • Daniel Penksa
    Principal Accounting Officer, Controller

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.